The stock of Cyclerion Therapeutics Inc. (NASDAQ:CYCN) last traded at $0.63, down -7.36% from the previous session.
Data from the available sources indicates that Cyclerion Therapeutics Inc. (NASDAQ:CYCN) is covered by 1 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $4.00 and a low of $4.00, we find $4.00. Given the previous closing price of $0.68, this indicates a potential upside of 488.24 percent. CYCN stock price is now -3.07% away from the 50-day moving average and -11.44% away from the 200-day moving average. The market capitalization of the company currently stands at $26.43M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
In total, 0 analysts have assigned it a hold rating, and 1 have given it a buy rating. Brokers who have rated the stock have averaged $4.00 as their price target over the next twelve months.
With the price target of $14, Truist recently initiated with Buy rating for Cyclerion Therapeutics Inc. (NASDAQ: CYCN). On September 24, 2021, Cantor Fitzgerald recently initiated its ‘Overweight’ rating on the stock quoting a target price of $7, while ‘Credit Suisse’ rates the stock as ‘Neutral’.
A total of 5.43% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CYCN stock. A new stake in Cyclerion Therapeutics Inc. shares was purchased by CITADEL ADVISORS LLC during the first quarter worth $7,000. In total, there are 51 active investors with 50.80% ownership of the company’s stock.
With an opening price of $0.6601 on Tuesday morning, Cyclerion Therapeutics Inc. (NASDAQ: CYCN) set off the trading day. During the past 12 months, Cyclerion Therapeutics Inc. has had a low of $0.35 and a high of $1.49. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.50, and a quick ratio of 2.50. The fifty day moving average price for CYCN is $0.6489 and a two-hundred day moving average price translates $0.7103 for the stock.
The latest earnings results from Cyclerion Therapeutics Inc. (NASDAQ: CYCN) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.31, missing analysts’ expectations of -$0.3 by -0.01. This compares to -$0.26 EPS in the same period last year. For the current quarter, analysts expect CYCN to generate $150k in revenue.
Cyclerion Therapeutics Inc.(CYCN) Company Profile
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer’s disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
